Stifel Nicolaus Cuts Affimed (NASDAQ:AFMD) Price Target to $4.00

Affimed (NASDAQ:AFMD) had its price objective trimmed by Stifel Nicolaus from $5.00 to $4.00 in a research note released on Friday,Benzinga reports. The brokerage currently has a hold rating on the biopharmaceutical company’s stock.

Other research analysts also recently issued research reports about the stock. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Affimed in a report on Friday. Cantor Fitzgerald restated an “overweight” rating on shares of Affimed in a report on Monday, September 9th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $16.00.

Affimed Stock Performance

Shares of NASDAQ AFMD opened at $3.48 on Friday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.71 and a current ratio of 2.71. Affimed has a one year low of $2.92 and a one year high of $8.95. The business’s 50-day moving average price is $3.49 and its two-hundred day moving average price is $4.51.

Affimed (NASDAQ:AFMD) last announced its quarterly earnings results on Thursday, September 5th. The biopharmaceutical company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($1.00) by ($0.09). Affimed had a negative net margin of 7,836.26% and a negative return on equity of 165.35%. The firm had revenue of $0.17 million during the quarter, compared to the consensus estimate of $1.67 million. Sell-side analysts anticipate that Affimed will post -4.25 earnings per share for the current year.

Institutional Trading of Affimed

Several large investors have recently modified their holdings of the company. Choreo LLC bought a new position in Affimed in the 2nd quarter worth $54,000. Intellectus Partners LLC grew its position in shares of Affimed by 12.2% in the third quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock valued at $317,000 after purchasing an additional 10,250 shares during the last quarter. Jane Street Group LLC bought a new position in shares of Affimed in the third quarter worth about $44,000. FMR LLC lifted its position in shares of Affimed by 30.0% during the 3rd quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock worth $59,000 after purchasing an additional 4,086 shares during the last quarter. Finally, Point72 Asset Management L.P. boosted its stake in Affimed by 4.6% during the 3rd quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock valued at $1,152,000 after purchasing an additional 15,108 shares during the period. 30.82% of the stock is owned by institutional investors.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.